Www. Clinical trial results.org The C-SIRIUS Study A The Canadian Multi-Center, Randomized, Double-Blind Study of the Sirolimus-Eluting Stent in the Treatment.

Slides:



Advertisements
Similar presentations
ENDEAVOR IV Acronym: ENDEAVOR IV. Lead investigator: Dr Martin Leon from Columbia University, New York Source: Transcatheter cardiovascular Therapeutics,
Advertisements

Copyleft Clinical Trial Results. You Must Redistribute Slides PEPCAD II ISR Study Paclitaxel-eluting devices: randomized comparison of the SeQuent™ please.
Paclitaxel-eluting Stents vs Brachytherapy for In-stent Restenosis (TAXUS V ISR) Trial Presented at The American College of Cardiology Scientific Session.
“Real World”: SVG, De Novo or Restenotic Coronary Artery Lesions Chronic Stable Angina, Silent Ischemia, Acute Coronary Syndromes Vessel Diameters:
M.Unverdorben; ACC March 2008 Martin Unverdorben Rotenburg/Fulda, Germany and Richmond, VA, USA Clinical Research Institute, Center for Cardiovascular.
EXCELLA BD Randomized Trial 12-month Results
Www. Clinical trial results.org The RAVEL Study A RAndomised (double blind) study with the Sirolimus coated BX™ VElocity balloon expandable stent (CYPHER™)
Four Drug Eluting Stent Trials Keith D Dawkins MD FRCP FACC Southampton University Hospital Keith D Dawkins MD FRCP FACC Southampton University Hospital.
3rd CEEGI Advisory Board1 Resolute in the DES era: Indications & Limitations Georgios I. Papaioannou, MD, MPH, FACC, FSCAI Athens Medical Center Cardiac.
Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE) Trial Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE)
DIABETES trial P Jiménez-Quevedo, M Sabaté, DJ Angiolillo, JA Gómez-Hospital, R Hernández-Antolín, J Goicolea, F Alfonso, C Bañuelos, J Escaned, R Moreno,
Chaim Lotan MD, Yaron Almagor MD, Karel Kuiper MD, M.J. Suttorp MD, William Wijns MD The SICTO Study CYPHER TM Sirolimus-eluting stent in Chronic Total.
Arterial Revascularization Therapies Part II: a non- randomized comparison of contemporary PCI and coronary artery bypass grafting (CABG) in patients with.
The REALITY Study Results. REALITY Study Design The REALITY Study : Prospective randomized clinical trial to evaluate the safety and efficacy of CYPHER®
Rapamycin- and Paclitaxel-Eluting Stents With Identical Biodegradable Polymeric Coating and Design Trial Presented at The American College of Cardiology.
NOBORI New Generation Drug Eluting Stent Clinical Data Danny Detiege Clinical Manager - Cardiology Terumo Europe N.V. Leuven, Belgium.
1 of Presented by Gregg W. Stone, MD, ACC PROMUS Stent is a private-labeled Xience V Everolimus Eluting Coronary Stent System manufactured.
Treatment of In-Stent Restenosis by Paclitaxel Coated PTCA Balloons Presented at The American Heart Association Scientific Session 2006 Presented by Dr.
Maurizio Menichelli MD San Camillo Hospital, Rome ( SESAMI Trial) Maurizio Menichelli Presenter Disclosure Information Nothing to Disclose Randomized trial.
DRUG ELUTION FOR ALL? THE CASE AGAINST Jim McLenachan Yorkshire Heart Centre, Leeds.
TAXUS ATLAS Trial Presented at The EuroPCR meeting Paris, France May 2006 Presented by Dr. Mark Turco TAXUS ATLAS 9-Month Results: Evaluation of TAXUS.
LONG-TERM OUTCOMES OF PERCUTANEOUS CORONARY INTERVENTION FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE: INITIAL CLINICAL EXPERIENCE. Graidis Ch. 1,
Slow-rate release polymer-based paclitaxel- eluting stent compared with bare stent in patients with single complex coronary lesions TAXUS V Presented at.
A Prospective, Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients TReated with Endothelial Progenitor Cell CapTuring Stents for De Novo.
Endeavor 4: A Randomized Comparison of a Zotarolimus- Eluting Stent and a Paclitaxel- Eluting Stent in Patients with Coronary Artery Disease Martin B.
Www. Clinical trial results.org Cypher sirolimus-eluting stent Primary Endpoint:  In-stent and late lumen loss at 9 months (determined by QCA) Secondary.
A Prospective, Randomized Trial of a Paclitaxel coated Balloon vs. uncoated Balloon Angioplasty in Patients with Drug- Eluting Stent Restenosis PEPCAD-DES.
RAVEL 4 YEAR FOLLOW-UP - Cordis Cardiology / Cardialysis – Euro-PCR – Sousa – 24 May 2005 RAVEL A RAndomised, double-blind study with the Sirolimus-eluting.
NEXT A Prospective, Randomized Trial Comparing Cre8, a Polymer-Free Stent Eluting Sirolimus, to a Paclitaxel-Eluting Stent Didier Carrié, MD,PhD On behalf.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Randomized Trial of Paclitaxel- Versus Sirolimus-Eluting.
Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at The American College.
From: Paclitaxel-Eluting Stents vs Vascular Brachytherapy for In-Stent Restenosis Within Bare-Metal StentsThe TAXUS V ISR Randomized Trial JAMA. 2006;295(11):
TAXUS II: Slow Release Formula An International, Randomized, Multicenter, Blinded Trial of TAXUSTM NIRxTM SR Stent Presented at TCT 2002.
NORSTENT Trial design: Patients with obstructive coronary artery disease were randomized to a drug-eluting stent (DES) (n = 4,504) versus a bare-metal.
Volume 54, Issue 1, Pages (August 2009)
Figure 3 One-year adverse events (death, post-discharge myocardial infarction, revascularization) after PCI according to patients who (A) would not have.
ABSORB Japan: 3-year Clinical and Angiographic Results of a Randomized trial Evaluating the Absorb Bioresorbable Vascular Scaffold vs. Metallic Drug-eluting.
LONG-DES II Trial Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent in the Treatment of Long Native Coronary.
Drug Eluting Balloons Bodo Cremers, MD
TAXUS IV Trial Slow-rate release polymer-based paclitaxel-eluting stent compared with bare stent in patients with single de novo coronary lesions Presented.
Stenting of Coronary Arteries in Non Stress/Benestent Disease
SIRIUS Trial: Diameter Restenosis
AcoArt I Trial design: Patients with femoropopliteal artery disease were randomized to paclitaxel-coated balloon angioplasty (n = 100) vs. standard peripheral.
Two-Year Extended Follow-up in Patients Receiving a Zotarolimus-eluting Stent in the E-Five Registry Martin T. Rothman, Ian T. Meredith, Keyur Parikh,
TAXUS II and IV: two-year follow-up
Long-term follow-up of the DIABETES I (DIABETes and sirolimus Eluting Stent) trial: P Jiménez-Quevedo, M Sabaté, DJ Angiolillo, JA Gómez-Hospital, R Hernández-Antolín,
BBK II Trial design: Patients undergoing a two-stent approach for a de novo bifurcation lesion were randomized in a 1:1 fashion to either culotte stenting.
The American College of Cardiology Presented by Dr. Maurits T. Dirksen
American College of Cardiology Presented by Dr. Stephan Windecker
FAIR Trial design: Patients with SFA in-stent restenosis (ISR) were randomized to either a paclitaxel-coated balloon (DCB) (dose 3.5 μg/mm2) or routine.
TAXUS II: Moderate Release Formula An International, Randomized, Multicenter, Blinded Trial of TAXUSTM NIRxTM MR Stent Presented at TCT 2002.
REALITY: 8 month results
Kyoto University Hospital, Japan
Presented at ACC 2003 Late Breaking Clinical Trials
The American College of Cardiology Presented by Dr. Raimund Erbel
Large-Scale Registry Examining Safety and Effectiveness of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease Western.
SIRIUS: A U.S. Multicenter, Randomized, Double-Blind Study of the SIRolImUS-Eluting Stent in De Novo Native Coronary Lesions Presented at TCT 2002.
American Heart Association Presented by Dr. Julinda Mehilli
ENDEAVOR II Five-Year Clinical Follow-up
Gregg W. Stone, MD Columbia University Medical Center
ENDEAVOR III Multicenter Randomized Trial Clinical/MACE Angio/IVUS
Updated 3-Year Meta-Analysis of the TAXUS Clinical Trials Safety and Efficacy Demonstrated in 3,445 Randomized Patients Time allocation for this talk.
Presented at TCT 2006.
Martin B. Leon, David R. Holmes, Dean J. Kereiakes, Jeffrey J
TAXUS VI Randomized Trial of Moderate-Rate Release Polymer-Based Paclitaxel-Eluting TAXUS Stent for the Treatment of Longer Lesions Three Year Clinical.
MACE: Death, MI or TLR at 5 years
Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial
American College of Cardiology Presented by Dr. Adnan Kastrati
The American College of Cardiology Presented by Dr. A. Abazid
TYPHOON Trial Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at.
Presentation transcript:

www. Clinical trial results.org The C-SIRIUS Study A The Canadian Multi-Center, Randomized, Double-Blind Study of the Sirolimus-Eluting Stent in the Treatment of Patients with De Novo Coronary Artery Lesions Erick Schampaert, Eric A. Cohen, Francois Reeves, Laurence M. Title, M. Dean Traboulsi, Richard R. Mildenberger, Dominic Raco, Sylvain Plante, Jeffrey Popma Presented at ACC 2003 Late Breaking Clinical Trials A The Canadian Multi-Center, Randomized, Double-Blind Study of the Sirolimus-Eluting Stent in the Treatment of Patients with De Novo Coronary Artery Lesions Erick Schampaert, Eric A. Cohen, Francois Reeves, Laurence M. Title, M. Dean Traboulsi, Richard R. Mildenberger, Dominic Raco, Sylvain Plante, Jeffrey Popma Presented at ACC 2003 Late Breaking Clinical Trials

www. Clinical trial results.org C-SIRIUS: Background Sirolimus (Rapamune® - Wyeth Ayerst) is a naturally occurring macrocyclic antibiotic It is a potent immunosuppressive agent inducing late G1 cell cycle arrest ACC 2003 Late Breaking Trials

www. Clinical trial results.org C-SIRIUS: Study Design 100 patients with single de novo lesions in native coronary arteries mm in length and 2.5 to 3.0 mm in diameter, randomized trial in Canada to BX Velocity Stent Coated with Sirolimus (n=50) Uncoated BX Velocity Stent (n=50) Uncoated BX Velocity Stent (n=50) Clopidogrel for 2 months Major Adverse Cardiac Events (MACE) (Death / MI / CABG / TLR) 8 Month Angiographic study ACC 2003 Late Breaking Trials

www. Clinical trial results.org C-SIRIUS: 8 Month In-stent Angiographic Results Late Loss (mm) Binary Restenosis (%) MLD (mm) p < Bare Stent Bare Stent Sirolimus Coated Sirolimus Coated ACC 2003 Late Breaking Trials p < Bare Stent Bare Stent Sirolimus Coated Sirolimus Coated Bare Stent Bare Stent Sirolimus Coated Sirolimus Coated

www. Clinical trial results.org C-SIRIUS: 8 Month In-lesion Angiographic Results Late Loss (mm) Binary Restenosis (%) MLD (mm) p < Bare Stent Bare Stent Sirolimus Coated Sirolimus Coated ACC 2003 Late Breaking Trials p < Bare Stent Bare Stent Sirolimus Coated Sirolimus Coated Bare Stent Bare Stent Sirolimus Coated Sirolimus Coated

www. Clinical trial results.org Bare Stent Bare Stent Sirolimus Coated Sirolimus Coated p<0.001 MACE* TLR Non-Q-Wave MI C-SIRIUS: 9 Month Clinical Event Results MACE = Death/MI/Emergent CABG/TLR Bare Stent Bare Stent Sirolimus Coated Sirolimus Coated p<0.001 Bare Stent Bare Stent Sirolimus Coated Sirolimus Coated p=NS 1/50 2/50

www. Clinical trial results.org C-SIRIUS: Conclusions Treatment of a single de novo lesion with a sirolimus-eluting stent was associated with larger MLDs and a reduction in binary restenosis on 8 month angiographic follow-up The angiographic results were similar to those in RAVEL but in longer lesions (12-32 mm) with smaller reference diameters (mean 2.6 mm) MACE by 9 months was reduced in sirolimus-eluting stent arm but was driven entirely by target lesion revascularization (no deaths or Q- wave MIs in either arm) Patients will be followed for clinical events for 5 years Treatment of a single de novo lesion with a sirolimus-eluting stent was associated with larger MLDs and a reduction in binary restenosis on 8 month angiographic follow-up The angiographic results were similar to those in RAVEL but in longer lesions (12-32 mm) with smaller reference diameters (mean 2.6 mm) MACE by 9 months was reduced in sirolimus-eluting stent arm but was driven entirely by target lesion revascularization (no deaths or Q- wave MIs in either arm) Patients will be followed for clinical events for 5 years ACC 2003 Late Breaking Trials